© Mikael Blomkvist / Photo courtesy Pexels
On April 22, 2026, Acting Attorney General Todd Blanche issued a final order rescheduling FDA-approved marijuana drug products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. This marks the first time since 1970 that the federal government has recognized marijuana as having accepted medical use. However, the order explicitly distinguishes medical marijuana from recreational use, which remains classified as Schedule I and federally illegal.
For employers across every industry, not just cannabis businesses, this shift raises urgent questions about drug testing programs, workers’ compensation liability and insurance coverage. While the rescheduling is now official, the employment-related implications are still unfolding.
Drug Screening Policies: What Employers Should Be Considering
The rescheduling creates immediate complexity around drug testing. Employers can still prohibit marijuana use and maintain drug-free workplace policies, but the legal landscape supporting those policies is shifting, particularly for employers in regulated industries.
For employers subject to Department of Transportation regulations, the situation is especially uncertain. DOT drug testing regulations under 49 CFR Part 40 currently authorize testing only for Schedule I and Schedule II controlled substances. With medical marijuana now reclassified as Schedule III, a technical gap may eliminate the legal authority to test for it in safety-sensitive positions, including commercial truck drivers, pilots, bus drivers, train engineers and pipeline workers. The DOT has stated that marijuana remains prohibited for safety-sensitive employees, but regulatory updates will be necessary to maintain testing authority. Industry advocates are pushing for a formal “safety carve-out” that would preserve marijuana testing requirements for safety-sensitive roles regardless of scheduling status.
For non-DOT employers, rescheduling is likely to increase Americans with Disabilities Act accommodation requests. Courts have historically rejected ADA claims related to medical marijuana use because marijuana was federally illegal. Now that medical marijuana has Schedule III status and federal recognition of accepted medical use, employees may argue that prescribed marijuana should be treated like any other prescription medication under disability accommodation laws. Legal experts suggest employers will likely retain the right to prohibit marijuana use that poses a direct safety threat, but individualized assessments may become necessary rather than blanket bans.
State laws add further complexity. Some states already prohibit discrimination against medical marijuana cardholders, while others explicitly allow employers to maintain zero-tolerance policies. Rescheduling does not preempt state protections or state restrictions; it simply changes the federal baseline.
Employers should also prepare for ongoing challenges with THC detection. Unlike alcohol, THC can remain in a person’s system for weeks after consumption, making it nearly impossible to determine impairment at the time of a workplace incident based on a urine test alone. This issue exists today and is not resolved by rescheduling. The likely shift will be toward greater emphasis on supervisor training for recognizing real-time impairment through behavioral observations rather than relying solely on metabolite testing that cannot prove current intoxication.
What employers should do now: review current drug testing policies with legal counsel to ensure they remain legally defensible post-rescheduling, communicate clearly with employees about continuing workplace policies, confirm drug testing panels and protocols with third-party administrators, and increase supervisor training on documenting observable signs of impairment rather than relying exclusively on test results.
Workers Compensation and Insurance: Navigating Likely Changes
Workers’ compensation reimbursement for medical marijuana has been one of the most inconsistent areas of employment law, and rescheduling may finally force resolution.
Currently, six states require workers’ compensation coverage for medical marijuana: Connecticut, Minnesota, New Hampshire, New Jersey, New Mexico and New York. Several states, including Maine, Massachusetts, Florida, North Dakota, Ohio and Washington, explicitly prohibit reimbursement. The primary legal argument against reimbursement has been that requiring insurance carriers to pay for marijuana could implicate them in violating the federal Controlled Substances Act.
With medical marijuana now rescheduled to Schedule III and federally recognized as having accepted medical use, that legal argument weakens considerably. States that currently prohibit coverage may face legal challenges to those restrictions, and insurance carriers may no longer be able to rely on federal illegality as grounds for denial. However, rescheduling does not automatically mandate coverage nationwide. State legislatures and workers’ compensation boards still control whether medical marijuana qualifies as a reimbursable treatment, meaning employers should expect continued state-by-state variation in the near term.
A related workers’ compensation concern involves injury claims where marijuana use is detected. Many state laws create a rebuttable presumption of intoxication if an employee tests positive for drugs following a workplace accident, which can reduce or eliminate benefits. Medical marijuana cardholders have not typically been exempted from this presumption, even in states with legal medical programs. The fundamental problem remains: a positive urine test shows only THC metabolites, not active impairment, meaning employees who used marijuana days earlier while off-duty can be penalized for workplace injuries sustained while sober.
Rescheduling may shift how courts and workers’ compensation boards treat these cases. Medical marijuana is now more analogous to prescription medications like opioids, drugs that are legal when prescribed but can still support benefit denials if they contribute to workplace accidents. Employers will likely need more sophisticated approaches to post-accident drug testing, potentially including blood tests that can better indicate recent use rather than relying exclusively on urine screens.
Employment Practices Liability Insurance may also see increased claims. EPLI policies often cover disputes related to discrimination or wrongful termination. As medical marijuana gains federal legitimacy and disability laws potentially extend protections to prescribed users, EPLI claims related to accommodation denials or adverse employment actions could rise. Employers should review their EPLI coverage with brokers and discuss potential exposure related to marijuana policies.
What employers should do now: review workers’ compensation procedures with legal and insurance advisors in light of rescheduling, ensure post-accident drug testing protocols comply with state-specific requirements, prepare for possible increases in medical marijuana reimbursement requests, and monitor state legislative activity for changes to workers’ compensation drug testing presumptions.
The Path Forward: Clarity Will Take Time
The April 2026 rescheduling order represents a fundamental shift in federal marijuana policy, but it does not resolve all employment-related questions. The order explicitly states that it applies only to FDA-approved drug products and state-licensed medical marijuana, not recreational use. Employers can still prohibit marijuana use in the workplace and maintain drug-free policies, but the legal foundations supporting those policies are changing.
The smartest approach is proactive preparation combined with clear communication. Employees may misunderstand rescheduling as blanket legalization or assume workplace policies have changed. Employers should clarify that current policies remain in effect, marijuana use is still prohibited during work hours and in safety-sensitive roles, and any policy updates will be communicated once legal and regulatory guidance becomes clearer.
DOT-regulated employers face the most immediate uncertainty and should monitor closely for regulatory updates that address testing authority for Schedule III substances. All employers should expect increased accommodation requests from medical marijuana users and prepare individualized assessment processes rather than relying on categorical denials.
Rescheduling reduces some federal-state conflicts but does not eliminate the need for careful, jurisdiction-specific policy management. Employers who consult legal counsel now, audit employee handbooks for clarity, and train leadership on emerging legal risks will be better positioned as courts, legislatures and regulatory agencies work through the implications of this historic change.
LEGAL DISCLAIMER: This article provides general information about potential implications of marijuana rescheduling on employment policies. It is not legal advice. Employment laws vary significantly by state, industry and individual circumstances. Employers should consult with qualified legal counsel and HR professionals before making any changes to drug testing policies, employee handbooks, workers’ compensation procedures or insurance programs. The information presented here is current as of publication but subject to change as regulations continue to evolve.
Veronica “Vee” Castillo is founder of the Traveling Cannabis Writer, an international plant medicine storyteller and journalist with more than seven years documenting cannabis culture globally. Author of Cannabis Legacy Chronicles and former communications director for a leading minority cannabis trade association, she helps businesses transform their stories into strategic content driving measurable growth.